Efficacy and safety study of NNC0194-0499 administered in combination with semaglutide in subjects with non-alcoholic steatohepatitis: dose-ranging trialing, placebo-controlled
Project objectivesThe objectives of the projects are attributable to the fields of interest of the UDR of Clinical Medicine and Hepatology: 1. Innovative treatments of advanced metabolic liver disease (MAFLD/NASH) with international multicenter intervention trials; 2. Innovative treatments of Primary Biliary Cholangitis (PBC); 3. The scouting and the characterization of MAFLD/NASH and risk factors for the evolution of chronic liver disease, including any genetic predispositions; 4. The scouting of cases of chronic Hepatitis C Virus (HCV) infection that are today susceptible to effective and well-tolerated treatment, even in elderly patients or with advanced liver disease; 5. Characterization and innovative treatments of sarcopenia in advanced chronic liver disease or malignancy; 6. Characterization of malignant and benign hepatic nodules using non-invasive techniques of temporary elastometry. |
Start and end date |
| October 2022 - Ongoing |
Project Manager |
| Picardi - Principal Investigator |
Coordinating institution of the project |
| UCBM |
Funding source(s). |
| Novo Nordisk |